Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cytek Biosciences Q2 2024 GAAP EPS $(0.08) Misses $(0.03) Estimate, Sales $46.617M Miss $49.526M Estimate

Author: Benzinga Newsdesk | August 06, 2024 04:22pm
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.03) by 166.67 percent. The company reported quarterly sales of $46.617 million which missed the analyst consensus estimate of $49.526 million by 5.87 percent. This is a 6.19 percent decrease over sales of $49.693 million the same period last year.

Posted In: CTKB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist